Funded Startups in Stevenage
The largest disclosed round in this Stevenage list is Gyroscope Therapeutics’ $149M Series C (2021-03-26), which dwarfs the rest of the disclosed amounts,…
The largest disclosed round in this Stevenage list is Gyroscope Therapeutics’ $149M Series C (2021-03-26), which dwarfs the rest of the disclosed amounts, with the next-largest being NeRRe Therapeutics at $28M (2021-07-07) and Freeline at $26M (2022-03-10). Sector is highly concentrated: 6 of the 7 entries are Biotechnology (Laverock Therapeutics 2023-09-28, Freeline 2022-03-10, NeRRe Therapeutics 2021-07-07, Gyroscope Therapeutics 2021-03-26, Myricx Pharma 2020-11-16, ReViral 2020-08-25), while the remaining one is Hardware (Civo 2021-09-17).
The rounds also cluster by time around mid-2021, with three biotech-focused financings in a short window: Gyroscope Therapeutics ($149M) on 2021-03-26, NeRRe Therapeutics ($28M) on 2021-07-07, and Civo’s Hardware round on 2021-09-17. The dated entries span 2020-08-25 (ReViral) to 2023-09-28 (Laverock Therapeutics), and stages are mixed with 2 entries missing a stage classification (Myricx Pharma on 2020-11-16 and ReViral on 2020-08-25).
Most recent rounds
7 shownRelated listings
Frequently asked
What stands out in deal size among these recent Stevenage financings?
Gyroscope Therapeutics’ $149M Series C on 2021-03-26 is a clear outlier versus the next-largest disclosed rounds of $28M (NeRRe Therapeutics, 2021-07-07) and $26M (Freeline, 2022-03-10).
Is there a biotech concentration and does it show up across the stages listed?
Biotechnology accounts for 6 of 7 companies (Laverock Therapeutics, Freeline, NeRRe Therapeutics, Gyroscope Therapeutics, Myricx Pharma, ReViral), while only Civo is categorized as Hardware (2021-09-17). Stage labels are still present for most of those biotech rounds: only Myricx Pharma (2020-11-16) and ReViral (2020-08-25) have a blank stage.
Do the rounds cluster in a particular time window rather than spreading evenly across 2020–2023?
Yes. Several entries cluster in 2021, including Gyroscope Therapeutics on 2021-03-26 ($149M) and NeRRe Therapeutics on 2021-07-07 ($28M), with Civo’s 2021-09-17 Hardware round ($2M) arriving shortly after. Overall, dates span from 2020-08-25 (ReViral) to 2023-09-28 (Laverock Therapeutics).
Which disclosed amounts are at the extremes (smallest and second-smallest) for this city page?
The smallest disclosed amount is Civo’s $2M on 2021-09-17, far below the next-lowest disclosed amount of $5M (Myricx Pharma on 2020-11-16). These extremes sit alongside much larger biotech financings like ReViral’s $44M (2020-08-25) and Gyroscope’s $149M (2021-03-26).
How many entries are missing stage labels, and does that affect which firms are easiest to benchmark by stage?
2 of the 7 rows have a blank stage classification: Myricx Pharma ($5M, 2020-11-16) and ReViral ($44M, 2020-08-25). That leaves the remaining 5 entries with explicit stages such as Seed (Laverock Therapeutics, $16M, 2023-09-28), Post-IPO Equity (Freeline, $26M, 2022-03-10), and Series B/C (NeRRe Therapeutics, $28M, 2021-07-07; Gyroscope Therapeutics, $149M, 2021-03-26).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.